Upgrade to SI Premium - Free Trial

Bristol-Myers Squibb Co. (BMY) PT Lowered to $51 at BMO Capital; 'IO NSCLC Complexity Increases'

February 6, 2018 6:51 AM
BMO Capital analyst Alex Arfaei lowered his price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $51.00 (from $52.00) while ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change

Next Articles